ReviewReviews in endocrine & metabolic disorders2016
Endocrine manifestations of systemic mastocytosis in bone.
Review in Reviews in endocrine & metabolic disorders, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 39 citations in OpenAlex.
- Management of skeletal-related events and fracture prevention in systemic mastocytosis.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2026Review
- Denosumab as a Potential Disease-Modifying Treatment in Indolent Systemic Mastocytosis-Related Osteoporosis.JCEM case reports · 2026Article
- Evaluating Melanoma Risk in Adult Mastocytosis: Potential Impact of Detection Bias - A Registry-based Study (Sweden).Acta dermato-venereologica · 2025Article
- Rare Genetic and Uncommon Morphological Entities in Adults with Acute Myeloid Leukemia.Current oncology reports · 2025Review
- Mastocytosis.Nature reviews. Disease primers · 2025Review
- Epidemiology of mastocytosis: a population-based study (Sweden).Acta oncologica (Stockholm, Sweden) · 2024Article
- Approach to Acute Myeloid Leukemia with Increased Eosinophils and Basophils.Journal of clinical medicine · 2024Review
- Case Report: Multidisciplinary management of a patient with indolent systemic mastocytosis and refractory symptoms.Frontiers in allergy · 2024Article
- Skin and bones: systemic mastocytosis and bone.Endocrinology, diabetes & metabolism case reports · 2023Article
- Roles of focal adhesion proteins in skeleton and diseases.Acta pharmaceutica Sinica. B · 2023Review
- How to evaluate the patient with a suspected mast cell disorder and how/when to manage symptoms.Hematology. American Society of Hematology. Education Program · 2022Article
- Osteoporosis Caused by Systemic Mastocytosis: Prevalence in a Cohort of 8392 Patients with Osteoporosis.Calcified tissue international · 2021Article
- Systemic mastocytosis with flushing and hypotension: A case report and literature review.Experimental and therapeutic medicine · 2021Article
- Systemic Mastocytosis: Multidisciplinary Approach.Mediterranean journal of hematology and infectious diseases · 2021Review
- Hematological Diseases and Osteoporosis.International journal of molecular sciences · 2020Review
- Hypertryptasemia and Mast Cell-Related Disorders in Severe Osteoporotic Patients.Mediators of inflammation · 2020Article
- The Role of Mast Cells in Bone Metabolism and Bone Disorders.Frontiers in immunology · 2020Review
- Systemic Mastocytosis and Essential Thrombocythemia: Case Report and Literature Overview.Medicina (Kaunas, Lithuania) · 2019Review
- Mast Cell Mediators Inhibit Osteoblastic Differentiation and Extracellular Matrix Mineralization.The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society · 2017Article
- Neuroendocrinology of the skin.Reviews in endocrine & metabolic disorders · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Systemic Mastocytosis (SM) is characterized by accumulation of clonal, neoplastic proliferations of abnormal mast cells (MC) in one or more organ system other than skin. Presence of these multifocal clusters of abnormal mast cells is an essential feature of SM. Frequently associated with D816V (KIT) mutation, the presence of this mutation and elevated serum tryptase are minor criteria for diagnosis. SM manifestations depend on the degree of mast cell proliferation, activation and degranulation. SM has a variable prognosis and presentation, from indolent to "smoldering" to life-threatening disease. Bone manifestations of SM include: osteopenia with or without lytic lesions, osteoporosis with or without atraumatic fracture, osteosclerosis with increased bone density, and isolated lytic lesions. Male sex, older age, higher bone resorption markers, lower DKK1 level, lower BMD, absence of urticaria pigmentosa, and alcohol intake are all associated with increased risk of fracture. Treatment of SM is generally palliative. Most therapy is symptom-directed; and, infrequently, chemotherapy for refractory symptoms is indicated. Anti-histamines may alleviate direct bone effects of histamine. Bisphosphonates, including alendronate, clodronate, pamidronate and zoledronic acid are recommended as a first line treatment of SM and osteoporosis. Interferon α may act synergistically with bisphosphonates. As elevation of RANKL and OPG is reported in SM, denosumab could be an effective therapy for bone manifestations of SM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.